Trials / Completed
CompletedNCT00428896
A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
A Pilot Feasibility Study to Evaluate the Efficacy of ZD1839 (IRESSA) in Eliminating Chemo- and Hormone- Resistant Cytokeratin-Positive Tumour Cells Circulating in the Blood of Women With Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University Hospital of Crete · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Based on preclinical data, ZD1839 is considered a novel and promising therapeutic approach with potential application in the treatment of human breast cancer. Therefore it could be very important and clinically relevant to know if ZD1839 is capable of eliminating occult tumour cells circulating in the blood of breast cancer patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD1839 | ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2007-01-30
- Last updated
- 2008-07-21
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT00428896. Inclusion in this directory is not an endorsement.